Cover Image
市場調查報告書

全球血友病市場分析

Global Hemophilia Market Report: 2016 Edition

出版商 Koncept Analytics 商品編碼 246749
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
全球血友病市場分析 Global Hemophilia Market Report: 2016 Edition
出版日期: 2016年04月11日 內容資訊: 英文 52 Pages
簡介

本報告提供全球血友病治療相關市場最新趨勢相關分析,市場特徵和整體結構,開發治療的最新情形,市場推動因素和今後的課題,競爭環境,主要企業簡介與產業策略等調查,今後的市場趨勢評估。

第1章 血友病:概要

  • 血友病的種類
  • 徵兆
  • 治療方法

第2章 市場概況

  • 全球血友病市場
    • 盛行率
    • 診斷及治療
    • 市場收益
    • A型血友病用血液凝固蛋白質第八凝血因子(FVIII)需求
    • 基因重組第八凝血因子的供給能力
    • A型血友病的市場收益
    • B型血友病的市場收益
    • 血友病抑制劑市場收益
  • 美國市場
    • 接受治療的患者數(年度)
    • 市場收益
    • 接受治療的A型血友病患者數(年度)
    • A型血友病市場收益
    • 接受治療的A型血友病患者數(年度)
    • 接受治療的B型血友病患者數(年度)
    • B型血友病市場收益
    • 血友病抑制劑治療患者數(年度)
    • 血友病抑制劑市場收益
    • von Willebrand因子市場收益
  • 歐洲市場
    • 患者數
    • A型血友病患者數
    • A型血友病治療:重症度別
    • B型血友病患者數
    • B型血友病治療:重症度別

第3章 市場動態

  • 成長推動因素
    • 基因改造型第八凝血因子的普及
    • 醫療費用支出的增加
    • 低所得國的治療方法的新的有效利用方法
    • 診斷率的增加
  • 主要趨勢
    • 預防的轉變
    • 遺傳基因療法
    • 引進半衰期長的產品
  • 課題
    • 治療的高成本
    • 轉換新的治療方法、產品的阻力

第4章 競爭情形

  • 各市場佔有率
  • 各財務狀況

第5章 企業簡介

  • Shire PLC
    • 產業概要
    • 主要的財務指標
    • 產業策略
  • Bayer Group
  • Novo Nordisk
  • Pfizer, Inc.

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

Hemophilia refers to a set of hereditary genetic disorders that impairs the body's ability to control blood clotting, which controls bleeding when a blood vessel is broken. People with hemophilia lack, either partially or completely, an essential clotting factor needed to form stable blood clots. In the absence of a treatment, uncontrolled internal bleeding can occur, causing stiffness, pain, severe joint damage and even death. Depending upon the coagulation factor deficiency, there are different types of hemophilia such as Hemophilia A, Hemophilia B, Hemophilia C, Von Willebrand disease and Hemophilia with Inhibitors.

Even though Hemophilia is rare bleeding disorder, the number of people affected by it has been increasing with time. While mild hemophilia is easy to diagnose especially in kids, when they learn to move and walk, and get large bruises from minute falls, severe hemophilia patients need to go for periodic transfusion of the respective factors so as to avoid the event of life-threatening bleeding episodes. Such a periodic transfusion is done through what is commonly known as the replacement therapy. With increasing sophistication and modernization of technology, demand for advanced treatment options increases, thereby making the entire market grow.

The key factors which are anticipated to drive this market include increasing penetration of recombinant factor VIII, increasing healthcare expenditure, emerging use of treatments in low income countries and increasing diagnosis rates. Some of the noteworthy progresses of this industry include the increasing adoption of prophylaxis therapy, introduction of extended half-life products and gene therapy. However, the growth of respective industry is challenged by the high cost of treatments and high reluctance by patients to switch to new treatments/products.

The report provides a comprehensive study of global hemophilia market and also major regional markets. Furthermore, market dynamics such as key trends and development; and challenges are analyzed in depth. The global hemophilia industry is highly competitive consisting of several large companies including the Shire Plc, Bayer Group, Pfizer Inc, Novo Nordisk etc. The competitive landscape of the respective market, along with the company profiles of the leading players are also discussed in detail.

Table of Contents

1. Overview

  • 1.1 Types of Hemophilia
    • 1.1.1 Hemophilia A
    • 1.1.2 Hemophilia B
    • 1.1.3 Hemophilia C
    • 1.1.4 Hemophilia with Inhibitors
    • 1.1.5 Von Willebrands Disease
  • 1.2 Signs and Symptoms
  • 1.3 Treatments of Hemophilia
    • 1.3.1 Replacement Therapy

2. Market Analysis

  • 2.1 Global Hemophilia Market
    • 2.1.1 Global Hemophilia Prevalence
    • 2.1.2 Global Hemophilia Diagnosis and Treatment
    • 2.1.3 Global Hemophilia Market Revenue
    • 2.1.4 Global Demand for FVIII for Hemophilia A
    • 2.1.5 Global Supply Capacity of Recombinant FVIII for Hemophilia
    • 2.1.6 Global Hemophilia A Market Revenue
    • 2.1.7 Global Hemophilia B Market Revenue
    • 2.1.8 Global Hemophilia with Inhibitors Market Revenue
  • 2.2 The US Hemophilia Market
    • 2.2.1The US Hemophilia Patients Treated per Year
    • 2.2.2 The US Hemophilia Market Revenue
    • 2.2.3 The US Hemophilia A Patients Treated per Year
    • 2.2.4 The US Hemophilia A Market Revenue
    • 2.2.5 The US Hemophilia B Patients Treated per Year
    • 2.2.6 The US Hemophilia B Market Revenue
    • 2.2.7 The US Hemophilia with Inhibitors Patients Treated per Year
    • 2.2.8 The US Hemophilia with Inhibitors Market Revenue
    • 2.2.9 The US Von Willebrand Factor Market Revenue
  • 2.3 Europe Hemophilia Market
    • 2.3.1 Europe Hemophilia Patients
    • 2.3.2 Europe Hemophilia A Patients
    • 2.3.3 Europe Hemophilia A Therapy by Severity
    • 2.3.4 Europe Hemophilia B Patients
    • 2.3.5 Europe Hemophilia B Therapy by Severity

3. Market Dynamics

  • 3.1 Growth Drivers
    • 3.1.1 Increasing Penetration of Recombinant FVIII
    • 3.1.2 Increasing Healthcare Expenditures
    • 3.1.3 Emerging Use of Treatments in Low Income Countries
    • 3.1.4 Increasing Diagnosis Rate
  • 3.2 Key Trends
    • 3.2.1 Increasing adoption of Prophylaxis
    • 3.2.2 Gene Therapy
    • 3.2.3 Introduction of Extended Half-Life Products
  • 3.3 Challenges
    • 3.3.1 High Cost of Treatment
    • 3.3.2 Reluctance to Switch to New Treatments/Products

4. Competitive Landscape

  • 4.1 Competition by Market Share
    • 4.1.1 Hemophilia Market Share
    • 4.1.2 Hemophilia A Market Share
  • 4.2 Competition by Financials
    • 4.2.1 Competition by Market Cap
    • 4.2.2 Competition by Profit Margin

5. Company Profiles

  • 5.1 Shire PLC
    • 5.1.1 Business Overview
    • 5.1.2 Financial Overview
    • 5.1.3 Business Strategies
  • 5.2 Bayer Group
    • 5.2.1 Business Overview
    • 5.2.2 Financial Overview
    • 5.2.3 Business Strategies
  • 5.3 Novo Nordisk
    • 5.3.1 Business Overview
    • 5.3.2 Financial Overview
    • 5.3.3 Business Strategies
  • 5.4 Pfizer Inc.
    • 5.4.1 Business Overview
    • 5.4.2 Financial Overview
    • 5.4.3 Business Strategies

List of Charts

  • Types of Hemophilia
  • Global Hemophilia Prevalence (2015)
  • Global Hemophilia Diagnosis and Treatment Ratio (2015)
  • Global Hemophilia Market Revenue (2015E-2020F)
  • Global Hemophilia Revenue Share by Category (2015E)
  • Global Hemophilia Revenue Share by Category -Forecast (2020)
  • Global FVIII Demand by Volume (2011-2015E)
  • Global FVIII Demand by Category - Volume (2015E-2017E)
  • Global Supply Capacity of Recombinant FVIII - Actual (2011-2015E)
  • Global Supply Capacity of Recombinant FVIII - Forecast (2016F-2017F)
  • Global Hemophilia A Market Revenue (2015E-2020F)
  • Global Hemophilia A Revenue Share by Category (2015E)
  • Global Hemophilia B Market Revenue (2015E-2020F)
  • Global Hemophilia with Inhibitors Market Revenue (2015E-2020F)
  • The US Hemophilia Patients Treated per Year (2013-2020F)
  • The US Hemophilia Market Revenue (2013-2015E)
  • The US Hemophilia Market Revenue - Forecast (2016F-2020F)
  • The US Hemophilia A Patients Treated per Year (2013-2020F)
  • The US Hemophilia A Market Revenue (2013-2020F)
  • The US Hemophilia B Patients Treated per Year (2013-2020F)
  • The US Hemophilia B Market Revenue (2013-2020F)
  • The US Hemophilia with Inhibitors Patients Treated per Year (2013-2020F)
  • The US Hemophilia with Inhibitors Market Revenue (2013-2020F)
  • The US Von Willebrand Factor Market Revenue (2013-2020F)
  • Europe Hemophilia Patients (2014-2020F)
  • Europe Hemophilia A Patients (2014-2020F)
  • Europe Hemophilia A Patients by Severity (2015E)
  • Europe Hemophilia A Therapy by Severity (2015E)
  • Europe Hemophilia B Patients (2015E-2020F)
  • Europe Hemophilia B Patients by Severity (2015E)
  • Europe Hemophilia B Therapy by Severity (2015E)
  • Penetration of Recombinant FVIII (2014)
  • Global Healthcare Expenditure Per Capita (2009-2014E)
  • Global Per Capita Usage of FVIII by Income Groups (2014)
  • Prophylaxis Therapy Usage by Category (2015E)
  • Global Hemophilia Market Share (2015E)
  • Global Hemophilia A Market Share (2015E)
  • Market Capitalization Comparison (2015)
  • Gross Profit Margin Comparison (2015)
  • Revenue Share by Product Category, Shire PLC (2015)
  • Revenue and Net Income, Shire PLC (2011-2015)
  • Revenue Share by Business Segments, Bayer Group (2015)
  • Revenue and Net Income, BAYER (2011-2015)
  • Revenue Share by Business Segments, Novo Nordisk (2015)
  • Revenue and Net Income, Novo Nordisk (2011-2015)
  • Revenue Share by Business Segments, Pfizer Inc. (2015)
  • Revenue and Net Income, Pfizer (2011-2015)

List of Tables

  • Gene Therapy Products under Development (2015)
  • Extended Half-Life Products under Development (2015)
Back to Top